Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhalla

Showing results (141-150 of 189) with videos related to

Pageof 19
Sort By:
Cancer Research|March 7, 2014
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemiaWarren Fiskus, Nakhle Saba, Min Shen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 13, 2018
Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune ChangesAndrew R DiNardo, Tomoki Nishiguchi, Emily M Mace, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.
Blood|October 16, 2009
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cellsYongchao Wang, Warren Fiskus, Daniel G Chong, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 19, 2021
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin <i>β</i>-Like 1-<i>β</i>-Catenin Protein ComplexRaffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, et al.
Blood Cancer Journal|February 5, 2024
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)Christopher P Mill, Warren C Fiskus, Courtney D DiNardo, et al.
Molecular Cancer Therapeutics|January 18, 2014
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cellsWarren Fiskus, Sunil Sharma, Jun Qi, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Leukemia|March 28, 2023
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1Christopher P Mill, Warren Fiskus, Kaberi Das, et al.
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Pageof 19

Showing results (141-150 of 189) with videos related to

Sort By:
Pageof 19
Cancer Research|March 7, 2014
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemiaWarren Fiskus, Nakhle Saba, Min Shen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 13, 2018
Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune ChangesAndrew R DiNardo, Tomoki Nishiguchi, Emily M Mace, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.
Blood|October 16, 2009
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cellsYongchao Wang, Warren Fiskus, Daniel G Chong, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 19, 2021
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin <i>β</i>-Like 1-<i>β</i>-Catenin Protein ComplexRaffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, et al.
Blood Cancer Journal|February 5, 2024
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)Christopher P Mill, Warren C Fiskus, Courtney D DiNardo, et al.
Molecular Cancer Therapeutics|January 18, 2014
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cellsWarren Fiskus, Sunil Sharma, Jun Qi, et al.
American Journal of Hematology|December 9, 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D DiNardo, Caitlin R Rausch, Christopher Benton, et al.
Leukemia|March 28, 2023
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1Christopher P Mill, Warren Fiskus, Kaberi Das, et al.
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Pageof 19